AIDS Behav by Lin, Xia et al.
Erectile Dysfunction Medication Prescription and Condomless 
Intercourse in HIV-infected Men Who have Sex with Men in the 
United States
Xia Lin1,2, Christine L. Mattson2, Mark Freedman2, and Jacek Skarbinski2 For the Medical 
Monitoring Project
1Epidemic Intelligence Service, Centers for Disease Control and Prevention (CDC), Atlanta, 
Georgia, USA
2Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention, CDC, Atlanta, Georgia, USA
Abstract
Using nationally representative data, we assessed the prevalence of erectile dysfunction 
medication (EDM) prescription, and its association with insertive condomless anal intercourse 
(CAI) with an HIV-serodiscordant partner among sexually-active HIV-infected men who have sex 
with men (MSM) receiving medical care in the United States. Overall, 14% (95% CI 12–16) were 
prescribed EDM and 21% (95% CI 19–23) engaged in serodiscordant CAI. MSM who were 
prescribed EDM were more likely to engage in insertive CAI with a serodiscordant casual partner 
than those not prescribed EDM after adjusting for illicit drug use before or during sex (adjusted 
prevalence ratio=1.38; 95% CI 1.01–1.88). We found no association with main partners. Only 40% 
(95% CI 36–44) of MSM prescribed EDM received risk-reduction counseling from healthcare 
professionals. Risk-reduction counseling should be provided at least annually to all HIV-infected 
persons as recommended, especially at the time of EDM prescription.
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Introduction
In 2010, an estimated 47,500 persons aged 13 years and older were newly infected with HIV 
in the United States [1]. Of the 38,000 new infections in men, 78% were attributed to male-
to-male sexual contact. With antiretroviral therapy (ART), the life expectancy of persons 
living with HIV has increased dramatically, approaching that of general population [2]. 
However, the prevalence of many chronic conditions appears to be higher in persons living 
with HIV, compared with the general populations [3, 4]. Erectile dysfunction (ED), the 
persistent inability to achieve or maintain an erection, is one such condition [5–7].
In the 1987–1989 Massachusetts Male Aging Study, 34.8% of men aged 40–70 years 
reported moderate to complete ED and in the 2001–2002 National Health and Nutrition 
Examination Survey, 18.4% of the US male population aged 20 years or older reported 
experiencing ED [8, 9]. More recently, the 2011 US National Health and Wellness Survey 
showed that 24.6% of men aged 40 years and older had ED [10]. However, the reported 
prevalence of ED has appeared to be higher among HIV-infected men, ranging 25%–74% in 
various study populations [5–7, 11–14]. Using more stringent methodological criteria 
including adequate sample sizes and a validated questionnaire for ED assessment, a 2014 
review found an ED prevalence of 50%–60% in HIV-infected men [15]. Although the 
reasons for the high prevalence of ED among HIV-infected men have not been fully 
elucidated, studies suggest that multiple factors may play a role. Previous research suggests 
that the direct and psychological effects of HIV, including change of body appearance, fear 
of infecting a partner, stigma, anxiety about disclosure, and comorbidities such as 
depression, hypertension and diabetes may contribute to increased ED prevalence. In 
addition, there is some evidence ED might be a side effect of ART, especially protease 
inhibitors [5, 6, 11, 15–17].
ED can be successfully treated. Phosphodiesterase type 5 inhibitors including sildenafil 
citrate, vardenafil hydrochloride, and tadalafil are effective peripheral vasodilator drugs for 
ED. They are legally available in the United States by prescription only; however, in an 
online survey of 603 US participants, 20.4% EDM users obtained the medications without a 
prescription, through pharmacies and online stores [18]. These drugs have been shown to 
alleviate the symptoms of ED and improve quality of life among those with ED. However, 
some studies suggest HIV-infected MSM are more likely to use EDM, and are more likely to 
engage in CAI compared with those who are not HIV-infected [19, 20]. MSM who use EDM 
are also more likely to engage in CAI [21, 22]. Thus, EDM use among HIV-infected MSM 
might contribute to HIV transmission, especially when the HIV-infected partner is in the 
insertive role. [23]. Most previous studies that document an association between EDM and 
CAI have relied on self-reported EDM use [24, 25]. If no health-care professionals are 
involved in the process of acquiring EDM, professional risk-reduction counseling is unlikely 
offered. Therefore, the association between self-reported EDM use and CAI does not 
necessarily mean the association between EDM prescription and CAI. Additionally, most 
previous investigations have employed convenience or geographically limited samples [22, 
24–28], which may not be generalizable.
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In this report, we present the prevalence of EDM prescription and HIV-serodiscordant CAI 
among sexually active HIV-infected MSM receiving medical care in the United States. We 
also assessed the association between EDM prescription and insertive CAI with a 
serodiscordant partner stratified by partner type (main and casual partners).
Methods
The Medical Monitoring Project (MMP) is a surveillance system designed to produce 
nationally representative, cross-sectional estimates of behavioral and clinical characteristics 
of HIV-infected adults in the United States [29–32]. For the data used in this analysis, MMP 
utilized a three-stage, complex sampling design in which US states and territories are 
sampled, followed by facilities providing outpatient HIV medical care in those jurisdictions, 
then HIV-infected adults (aged 18 years and older) receiving care in those facilities. The 
probability of being sampled at each of the three stages, states/territories, facilities, and 
patients, is proportional to the estimated HIV-infected population size at each sampling 
stage. This allows the data collected from sampled individuals to be representative of the 
HIV-infected population receiving medical care in the United States. Interview and medical 
record data were collected from HIV-infected persons receiving medical care during January 
– April of each year from 2009 through 2012. All sampled states and territories participated 
and the facility response rates ranged from 76%–85% across all years. Approximately 50% 
(ranging from 47% to 53% across all years) of eligible persons sampled from these facilities 
completed an interview and had their medical records abstracted. Data were weighted to 
account for unequal probabilities of selection and both facility and patient nonresponse [33, 
34]. We analyzed data on 4,465 sexually active MSM who had been diagnosed with HIV for 
at least 12 months before interview, which were weighted to represent sexually active HIV-
infected MSM receiving medical care in the United States during January to April each year 
2009 through 2012. The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention determined that MMP was a public health surveillance activity and not subject to 
federal institutional review board review [35, 36]. However, some jurisdictions obtained 
approval from local Institutional Review Boards. All participants provided informed consent 
to participate in the interview.
Measures
All self-reported information reflects behaviors and experiences during the 12 months prior 
to interview unless otherwise noted. Sexually active MSM were classified as men reporting 
any anal intercourse with a man. Serodiscordant CAI was defined as at least one episode of 
anal intercourse without a condom with a partner of unknown or negative HIV status. “Main 
partner” was defined as “a man you have sex with and whom you feel committed to above 
anyone else. This is a partner that you would call boyfriend, husband, significant other, or 
life partner.” “Casual partner” was defined as “a man you have sex with, but do not feel 
committed to or don’t know very well.” Depression was based on self-reported symptoms in 
the two weeks prior to interview using the Patient Health Questionnaire (PHQ-8) [37]. If the 
total depression score was >=5, it was classified as “major depression”; if the total 
depression score was between 2 and 4, it was classified as “other depression”. Self-reported 
socio-demographic characteristics included age, race and ethnicity, education, poverty 
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status, homeless status, in-jail status, and healthcare coverage. Self-reported behaviors 
included number of sex partners, binge drinking (defined as 5 or more alcohol drinks in one 
sitting in the past 30 days), any alcohol use before or during sex, any illicit drug use (both 
general use and use before or during sex, including heroin, cocaine, methamphetamine, other 
amphetamines or stimulants, steroids or hormones, painkillers, hallucinogens, 
methylenedioxymethamphetamine, ketamine, gamma-hydroxybutyrate, marijuana, and amyl 
nitrite), any CAI, any serodiscordant CAI, any serodiscordant CAI with a main partner, and 
any serodiscordant CAI with a casual partner. The calculated drug use variables were coded 
“yes” if the participant reported daily, weekly, monthly, or less than monthly use of any of 
the aforementioned substances. Other self-reported variables included time since HIV 
diagnosis, testing for STIs other than HIV, and whether risk-reduction counseling from a 
healthcare professional was received.
Information on ART and EDM prescriptions, viral load tests, and clinical HIV status was 
abstracted from medical records and was also restricted to the 12 months prior to interview 
unless otherwise noted. EDM prescription was defined as documentation of at least one 
prescription of sildenafil citrate, vardenafil hydrochloride, or tadalafil; durable viral 
suppression was defined as all viral load results in the medical record were less than 200 
copies/ml or undetectable.
Data analysis
For population characteristics and risk behaviors, and prevalence of serodiscordant CAI, we 
generated weighted percentages and 95% confidence intervals (CIs) for all sexually active 
MSM whose HIV diagnosis had been made at least 12 months before interview (June 2008–
May 2009 for the 2009 data cycle; June 2009–May 2010 for the 2010 cycle; June 2011–May 
2012 for the 2011 cycle; June 2012–May 2013 for the 2012 cycle). We performed Rao-Scott 
chi-square tests to assess differences between sexually active MSM who were prescribed 
EDM and those who were not. We used Wald F tests and crude prevalence ratios (PRs) 
generated from univariate logistic regression models to assess the crude associations 
between socio-demographic characteristics/risk factors and CAI.
We used multivariable logistic regression models to examine whether EDM prescription was 
independently associated with serodiscordant insertive CAI among sexually active MSM. 
We developed separate models for two outcome variables, insertive CAI with a 
serodiscordant main partner, and insertive CAI with a serodiscordant casual partner. The two 
outcomes were not mutually exclusive and were derived from two separate questions. For 
the first outcome measure, all sexually active MSM whose HIV diagnosis had been made at 
least 12 months before interview were grouped into two categories, “yes” if they had at least 
one insertive CAI with a serodiscordant main partner in the past 12 months and “no” if they 
did not have any insertive CAI with a serodiscordant main partner in the past 12 months, 
including those who did not have serodiscordant CAI at all, those who only had receptive 
serodiscordant CAI, and those who only had serodiscordant CAI with a casual partner, etc. 
The second outcome measure was defined similarly for insertive CAI with a serodiscordant 
casual partner. Using the statistical significance of an interaction term in a logistic regression 
model between EDM prescription and serodiscordant CAI, we assessed potential effect 
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modification caused by durable viral suppression because theoretically viral suppression 
status could modify the association between sexual risk behaviors and use of EDM. If the 
interaction term was significant (p<0.10), it was entered in the multivariable model 
containing potential confounders for reassessment. The interaction term stayed in the final 
model if it was significant (p<0.05) in the multivariable model. Similar to previous studies 
[24, 26, 27], we considered the following factors as potential confounders: race, age, 
education, depression, binge drinking, illicit drug use before or during sex. Durable viral 
suppression was only considered as a potential confounder if it was not a significant effect 
modifier. Our criteria for a potential confounder to be included in a final model were any 
factor that: 1) was associated with EDM prescription (p<0.10), 2) was associated with 
serodiscordant insertive CAI (p<0.10), and 3) caused 10% or more change on the association 
(measured by PR) between EDM and serodiscordant insertive CAI. All potential 
confounders that met these criteria were included in the final model. Because illicit drug use 
before or during sex has been established as a particularly important confounder in the 
literature [24, 26, 27], illicit drug use before or during sex was forced into the final models 
as an a priori covariate, regardless of whether it caused 10% or more change on the 
association between EDM and serodiscordant insertive CAI.
All analyses accounted for the complex sample design and unequal selection probabilities by 
using the survey procedures in SAS 9.3 [38] and SUDAAN 10.0.1 [39].
Results
Population characteristics
In total, 18,095 adults had both interview data and medical record data in the combined 
dataset from four collection cycles (June 2009–May 2013). Among the 5,821 MSM, 5,686 
had been diagnosed with HIV for at least 12 months. Of them, 4,465 MSM had at least one 
act of anal intercourse in the 12 months before interview and therefore considered sexually 
active. Among these sexually active MSM, an estimated 34% were under 40 years old, 51% 
were non-Hispanic whites, and 73% had more than high school education (Table 1). During 
the 12 months prior to interview, 91% were prescribed ART, 69% were durably virally 
suppressed, and 59% had ever been diagnosed with AIDS. Overall, 23% reported a positive 
STI test, 40% reported a negative STI test, and 36% reported not having been tested for 
STIs. In addition, 22% reported binge drinking and 40% reported illicit drug use. Forty-
seven percent drank alcohol and 27% used illicit drugs before or during sex (Table 1).
Of sexually active HIV-infected MSM receiving medical care in the United States, 14% 
(95% CI 12–16) were prescribed EDM. Statistically significant differences were seen in all 
socio-demographic and clinical characteristics between those who were prescribed EDM 
and those who were not prescribed EDM except depression status and self-reported STI 
testing (Table 1). Regarding self-reported sexual and drug-use behaviors, compared with 
MSM who were not prescribed EDM, those who were prescribed EDM were significantly 
less likely to be binge drinkers, but more likely to have more than 1 sex partner or use illicit 
drug before or during sex (Table 1).
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Of note, only 45% of all sexually active MSM received risk-reduction counseling from a 
healthcare professional in the 12 months before interview. MSM prescribed EDM were 
significantly less likely than MSM not prescribed EDM to have received such counseling 
(40% vs 46% respectively, p=0.035, Rao-Scott chi-square statistic = 4.43, Table 1).
Prevalence of CAI
Of all sexually active HIV-infected MSM receiving medical care (n=4,465), an estimated 
55% engaged in CAI, and 21% engaged in serodiscordant CAI; 77% (95% CI 75–78) had at 
least one main partner in the past 12 months, and 57% (95% CI 55–59) had at least one 
casual partner in the past 12 months; 6% engaged in insertive CAI with a serodiscordant 
main partner, and 7% did so with a serodiscordant casual partner (Table 1).
Relationship between EDM prescription and CAI
Durable viral suppression was not a statistically significant effect modifier in the logistic 
regression models. All potential confounders that met our criteria were assessed, but only 
age was identified in the model of insertive CAI with a serodiscordant main partner. Illicit 
drug use before or during sex did not meet our criteria for a confounder but was forced in 
both models as previously explained.
As shown in Table 2, the multivariable logistic regression models revealed that while the 
association between EDM prescription and insertive CAI with a serodiscordant main partner 
was not statistically significant, the association between EDM prescription and insertive CAI 
with a serodiscordant casual partner was statistically significant (p<0.05). Sexually active 
MSM who were prescribed EDM were significantly more likely to engage in insertive CAI 
with a serodiscordant casual partner than those who were not prescribed EDM (adjusted PR, 
1.38; 95% CI 1.01–1.88).
Discussion
To our knowledge, this analysis provides the first national prevalence estimates of EDM 
prescription among HIV-infected MSM receiving medical care in the United States. Our 
estimate that 14% of sexually active HIV-infected MSM were prescribed EDM in the past 12 
months is close to a previously published estimate that 12% of HIV-infected gay and 
bisexual men were prescribed sildenafil citrate from the Seropositive Urban Men’s 
Intervention Trial [40].
Our analysis is the first to confirm the association between EDM prescription and insertive 
CAI with a serodiscordant casual partner using nationally representative data. Our finding 
that HIV-infected MSM prescribed EDM were more likely to engage in insertive CAI with a 
serodiscordant casual partner is consistent with literature in terms of the general association 
between EDM use and sexual risk behavior [20, 22, 24–28, 41, 42]. However, we did not 
find a statistically significant association between EDM prescription and insertive CAI with 
a serodiscordant main partner, contrary to previous studies that suggested that MSM were 
more likely to have CAI with their main partners due to perceived low risk of HIV 
transmission, and most HIV transmissions among MSM were from main partners [43–45]. 
Many factors, such as HIV status of a sex partner, partner type, and sexual positioning, are 
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involved in the decision-making process but the majority of previous studies have only been 
able to consider a subset of these factors. We used a specific definition of sexual risk 
behavior (i.e., insertive CAI with a serodiscordant main partner or casual partner) to try to 
disentangle the relationship between EDM use and sexual risk behavior, and the differential 
associations between EDM prescription and CAI by partner type may suggest that HIV-
infected MSMs engage in different behaviors with their main partners. Future analysis at the 
event level (i.e. the occurrence of EDM use that precedes a given sexual act) is needed to 
further understand these differences.
The receptive anal sex partners of HIV-infected men are at high risk for HIV transmission if 
no HIV prevention strategy is used. A systematic review on onward transmission risks from 
an HIV-infected partner to an uninfected partner revealed that among all sexual behaviors, 
when the HIV-uninfected partner is the receptive partner, the risk for HIV transmission is 
highest [23]. In the current analysis, we found a significant association between EDM and 
insertive CAI with a serodiscordant casual partner. Although viral suppression may reduce 
HIV transmission [46], it does not modify the association between EDM prescription and 
serodiscordant CAI in our analysis. In other words, sexually active MSM who were 
prescribed EDM were more likely to engage in serodiscordant insertive CAI with a casual 
partner regardless of their viral suppression status. Since our analysis indicated that sexually 
active MSM were more likely to engage in insertive CAI with a serodiscordant casual 
partner when prescribed EDM, and the provision of risk-reduction counseling by medical 
providers can significantly reduce the prevalence of sexual risk behavior [47], we believe 
this has important prevention implications for HIV care providers. In addition to following 
recommended guidelines [48] to provide risk reduction counseling at least once a year for 
sexually active patients, when prescribing EDM to patients, providers may consider 
discussing the role of HIV treatment in preventing HIV transmission to partners [49] and 
assess whether their partners may be eligible for pre-exposure prophylaxis [50].
There are several limitations to this analysis and interpretation of these data. First, MMP 
participants are HIV-infected adults receiving medical care in the United States, so the 
findings based on these data cannot be generalized to US persons unaware of their HIV 
infection or those not receiving medical care, nor to populations outside the United States. 
Second, MMP data are cross sectional and the time frame for which we assessed EDM 
prescription and sexual acts without a condom was the 12 months before interview. Whether 
EDM prescription occurred before or after the CAI is unknown. Therefore, the association 
between EDM prescription and insertive CAI with a serodiscordant casual partner may mean 
that EDM facilitates risk behavior, or that MSM who are more likely to engage in risk 
behaviors are more likely to use EDM to enhance their sexual performance [27]. 
Nonetheless, targeted risk-reduction counseling provided at the time of EDM prescription 
should be beneficial. Third, our measure of durable viral suppression does not take into 
account fluctuation or unmeasured results, and risk behaviors and durable viral suppression 
of respondents may be different from non-respondents. However, MMP collected 
information on sampled patients and facilities including sex, age, race, length of time since 
diagnosis, and facility’s HIV patient load and was able to compare respondents and non-
respondents. Data were then weighted according to these analyses to minimize non-response 
bias. Fourth, patients may not take the prescribed EDM; alternatively, some patients may 
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take EDM that was obtained without prescription [18]. We were unable to account for non-
prescribed EDM use in the current analysis. Fifth, pre-exposure and post-exposure 
prophylaxis information were not captured in the analytic dataset so we were unable to 
assess whether the participants used these strategies for HIV prevention. Finally, the self-
reported information was collected by face-to-face or telephone interviews. Therefore, 
sexual risk behavior may be underreported due to social desirability bias.
Conclusions
Among sexually active HIV-infected MSM receiving medical care in the United States from 
2009 to 2012, those who were prescribed EDM were more likely to engage in insertive CAI 
with a serodiscordant casual partner than those not prescribed EDM. Only 40% of HIV-
infected MSM prescribed EDM received risk-reduction counseling despite recommendations 
that such counseling be provided at least once a year. Healthcare providers should assess risk 
behaviors and provide risk-reduction counseling to all HIV-infected persons as 
recommended by guidelines, especially at the time of EDM prescription.
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